281 results on '"Giles F. J."'
Search Results
2. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
Catalog
Books, media, physical & digital resources
3. Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib
4. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
5. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
6. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
7. MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
8. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
9. Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies
10. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
11. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
12. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
13. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
14. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
15. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1
16. Levels of soluble HLA-I and β2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy
17. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
18. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
19. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
20. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias
21. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia
22. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes
23. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
24. Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
25. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
26. Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study: 101
27. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia
28. A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome
29. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results: 158
30. Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma
31. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies
32. Clone wars in CML
33. Plasma as a source of mRNA for determining IgVH mutation status in patients with chronic lymphocytic leukaemia
34. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
35. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia
36. Granulocytic sarcoma of the pancreas: a report of two cases and literature review
37. Cusum Plotting Of Temperature Charts For Assessing Antimicrobial Treatment In Neutropenic Patients
38. Amenhotpe, Ikhnaton and the succession
39. P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER‐LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB‐ANALYSIS FROM THE PHASE 4 BYOND TRIAL.
40. EFFECT OF LIGHT OVERLOADS ON COUNTERMOVEMENT VERTICAL JUMP PERFORMANCE.
41. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
42. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
43. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
44. Targeting HSP90 for cancer therapy.
45. Aspiración transbronquial con aguja guiada por ultrasonografía endoscópica endobronquial en el diagnóstico de linfoma.
46. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
47. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
48. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
49. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
50. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.